AbbVie (NYSE:ABBV) Price Target Raised to $300.00

Posted by Geri Gentry on Oct 11th, 2026

AbbVie (NYSE:ABBV – Free Report) had its price objective boosted by JPMorgan Chase & Co. from $285.00 to $300.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other research firms have also commented on ABBV. Citigroup upped their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Guggenheim increased their target price on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Cantor Fitzgerald boosted their price target on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and boosted their target price for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $277.18.

View Our Latest Stock Analysis on ABBV

AbbVie Price Performance

AbbVie stock opened at $276.24 on Thursday. The company has a market cap of $488.06 billion, a PE ratio of 78.03, a P/E/G ratio of 1.26 and a beta of 0.24. The company has a fifty day moving average price of $259.06 and a two-hundred day moving average price of $236.63. AbbVie has a 12 month low of $190.75 and a 12 month high of $277.60.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm posted $2.97 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Institutional Trading of AbbVie

Hedge funds have recently bought and sold shares of the stock. Armstrong Advisory Group Inc. boosted its position in shares of AbbVie by 11.8% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 10,276 shares of the company’s stock valued at $2,688,000 after acquiring an additional 1,083 shares in the last quarter. Oak Grove Capital LLC boosted its stake in AbbVie by 38.0% in the 3rd quarter. Oak Grove Capital LLC now owns 61,750 shares of the company’s stock valued at $16,153,000 after buying an additional 17,000 shares in the last quarter. Gilpin Wealth Management LLC grew its position in AbbVie by 74.1% in the third quarter. Gilpin Wealth Management LLC now owns 893 shares of the company’s stock valued at $234,000 after acquiring an additional 380 shares during the period. jvl associates llc grew its position in AbbVie by 11.0% in the third quarter. jvl associates llc now owns 1,310 shares of the company’s stock valued at $343,000 after acquiring an additional 130 shares during the period. Finally, Friday Financial bought a new position in shares of AbbVie during the third quarter valued at $218,000. 70.23% of the stock is owned by institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

AbbVie Company Profile

(Get Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.